Home page

Rozanolixizumab

Product Item Number: XC978997 - 100 µg English Name: Rozanolixizumab Chinese Name: 罗扎诺利珠单抗

Commodity name： Rozanolixizumab

Category:

Control drug

Email:

taoweihong@constreambio.com

Product Inquiry

Product Specifications

Product item number	XC978997 -100µg
English name	Rozanolixizumab
Chinese name	Rozanolimab
Antibody source	Human
Clone Type	Monoclonal
Physical State	Liquid
Concentration	1 mg/mL
Subtype	IgG4q
Expression system	CHO-K1 stable cell line
Purification method	Affinity purified by Protein A
Buffer solution	0.2 μm filtered in PBS, pH 7.4, 10% glycerol
Purity	＞98% as determined by SDS-PAGE；＞98% as determined by SEC-HPLC

Storage conditions

Aliquot and store at -20°C to -80°C,Avoid repeat freeze-thaw cycles.

Precautions

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Product Introduction

Rozanolixizumab is a humanized IgG4 monoclonal antibody. On June 27, 2023, rozanolixizumab-noli was approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti- acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Rozanolixizumab inhibits the neonatal Fc receptor (FcRn), which plays a key role in recycling immunoglobulin G (IgG) antibodies in the body. By blocking FcRn, Rozanolixizumab reduces the levels of pathogenic IgG antibodies, which are involved in autoimmune diseases.

Documentary materials